Here's the Deal
Baird's Investment Banking Group is pleased to announce the following transaction:
CoreLab Partners, Inc.
Sale to JLL Partners, Inc.
Baird served as sole financial advisor to CoreLab Partners
CoreLab Partners, Inc. (“CoreLabs” or the “Company”), a portfolio company of Ampersand Capital Partners (“Ampersand”) and SV Life Sciences Advisers (“SV Life Sciences”), was recently acquired by a holding company controlled by JLL Partners, Inc. (“JLL Partners”). Simultaneously, JLL Partners recently completed its acquisition of BioClinica, Inc. (“BioClinica”) (NASDAQ:BIOC). The Company and BioClinica have merged to create a leading provider of medical imaging services and best-in-class eClinical solutions for clinical trials. Terms of the CoreLabs transaction have not been disclosed.
CoreLabs provides clinical trial sponsors with best-in-class centralized cardiac safety & efficacy services and independent medical image assessment solutions – all designed to facilitate successful new drug development in the pharmaceutical, biotechnology and medical device market sectors. CoreLabs' services include medical image management, interpretation and response assessment for clinical trials, with a particular focus on the oncology therapeutic area. CoreLabs provides regulatory support and digital image submission, as well as cost-effective cardiac safety assessments for development programs, support for clinical studies and equipment rental. The Company also offers worldwide ambulatory blood pressure monitoring services, digital ECG services and cardiac safety services.
Ampersand is a leading private equity firm focused on middle market growth equity investments in the Healthcare sector and has managed $1 billion over its 25 year history. Ampersand leverages its unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams.
SV Life Sciences is a leading international life sciences venture capital firm with approximately $2.0 billion of capital under management. SV Life Sciences employs a diversified strategy within life sciences in order to selectively capitalize on the expanding opportunity in biotech, medical devices and healthcare services.
JLL Partners is a leading private equity investment firm with approximately $4 billion of capital under management. Its investment philosophy is to partner with management teams and invest with them in companies they can continue to grow into market leaders. JLL Partners has invested in a variety of industries, with special focus on healthcare services, financial services and business services.
BioClinica is a leading provider of integrated, technology-enabled clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response and other solutions. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval.